Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Use of healthy volunteers drives clinical oncology drug development decision making.

Iwamoto M, Iannone R, Wagner JA.

Clin Pharmacol Ther. 2012 Nov;92(5):571-4. doi: 10.1038/clpt.2012.157. Epub 2012 Sep 26. No abstract available.

PMID:
23010649
2.

[Molecular targeted anticancer agents in the First in Human study--possibility for dosing healthy volunteers].

Kato R.

Nihon Yakurigaku Zasshi. 2012 Sep;140(3):131-4. Review. Japanese. No abstract available.

PMID:
22975828
3.

[Problems associated with molecular targeted drugs for cancer].

Kawaishi M, Koizum F, Nishio K.

Gan To Kagaku Ryoho. 2006 Oct;33(10):1373-9. Review. Japanese.

PMID:
17033223
4.

Clinical trial designs for targeted agents.

Ma BB, Britten CD, Siu LL.

Hematol Oncol Clin North Am. 2002 Oct;16(5):1287-305. Review.

PMID:
12512393
5.

Drug development in oncology: classical cytotoxics and molecularly targeted agents.

Kummar S, Gutierrez M, Doroshow JH, Murgo AJ.

Br J Clin Pharmacol. 2006 Jul;62(1):15-26. Review.

6.

Tissue-based approaches to study pharmacodynamic endpoints in early phase oncology clinical trials.

Ang JE, Kaye S, Banerji U.

Curr Drug Targets. 2012 Nov;13(12):1525-34. Review.

7.
8.

Next generation oncology drug development: opportunities and challenges.

Gutierrez ME, Kummar S, Giaccone G.

Nat Rev Clin Oncol. 2009 May;6(5):259-65. doi: 10.1038/nrclinonc.2009.38. Review.

PMID:
19390552
9.

Evaluation of tumor size response metrics to predict survival in oncology clinical trials.

Bruno R, Mercier F, Claret L.

Clin Pharmacol Ther. 2014 Apr;95(4):386-93. doi: 10.1038/clpt.2014.4. Epub 2014 Jan 13. Review.

PMID:
24419563
10.

[Dose optimization in clinical oncology: pharmacokinetic-pharmacodynamic relationship].

Canal P, Chatelut E.

Bull Cancer. 1996 Apr;83(4):256-65. Review. French.

PMID:
8680077
11.

Compressing drug development timelines in oncology using phase '0' trials.

Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, Collins J, Pickeral O, Low J, Steinberg SM, Gutierrez M, Yang S, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH.

Nat Rev Cancer. 2007 Feb;7(2):131-9. Review.

PMID:
17251919
12.

Development of target-based antineoplastic agents.

Stadler WM, Ratain MJ.

Invest New Drugs. 2000 Feb;18(1):7-16. Review.

PMID:
10830137
13.

Dose-toxicity models in oncology.

Adamina M, Joerger M.

Expert Opin Drug Metab Toxicol. 2011 Feb;7(2):201-11. doi: 10.1517/17425255.2011.543674. Review.

PMID:
21241201
14.

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Zandvliet AS, Schellens JH, Beijnen JH, Huitema AD.

Clin Pharmacokinet. 2008;47(8):487-513. Review.

PMID:
18611060
15.
16.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.

Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9. Review.

PMID:
18199854
17.

Immunotherapeutic strategies for neoplasia.

Talmadge JE.

Dev Biol Stand. 1992;77:17-28. Review. No abstract available.

PMID:
1426659
19.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ.

Clin Cancer Res. 2004 Jun 1;10(11):3885-96. Review. No abstract available.

20.

Pharmacokinetic-pharmacodynamic guided trial design in oncology.

van Kesteren Ch, Mathôt RA, Beijnen JH, Schellens JH.

Invest New Drugs. 2003 May;21(2):225-41. Review.

PMID:
12889741
Items per page

Supplemental Content

Write to the Help Desk